Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation
of cancer immunotherapies, announced that the Company will present at
the Biotech Showcase™ 2014 Conference being held at the Parc 55 Wyndham
San Francisco Union Square Hotel in San Francisco, CA.
Daniel J. O'Connor, Chief Executive Officer of Advaxis, will provide an
update on the Company on Wednesday, January 15, 2014 at 11:30AM Pacific
Interested parties can access a live audio webcast and slide
presentation at: http://www.media-server.com/m/p/nzctmxk8.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next
generation of cancer immunotherapies. Advaxis immunotherapies are based
on a novel platform technology using live, attenuated bacteria hat are
bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is
designed to redirect the powerful immune response all human beings have
to the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in Phase 1 and 2 clinical trials
for HPV-associated cancers: recurrent cervical cancer (completed Phase 2
study conducted in India), locally advanced cervical cancer (GOG/NCI
U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck
cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792, Mt.
Sinai study, Clinical Trials.gov Identifier NCT02002182), and anal
cancer (BrUOG U.S. study, Clinical Trials.gov Identifier NCT01671488).
Advaxis has over 15 distinct immunotherapies in various stages of
development, developed directly by Advaxis and through strategic
collaborations with recognized centers of excellence such as: the University
of Pennsylvania, the Georgia
Regents University Cancer Center, Icahn
School of Medicine at Mount Sinai, and others.
For more information please visit: www.advaxis.com
[ Back To NFVZone's Homepage ]